Background/Aims: Fibrocaps is a dry powder fibrin sealant containing human plasma-derived fibrinogen and thrombin. The safety, efficacy, and application methods for Fibrocaps were evaluated in an exploratory, first-in-human, noncomparative, clinical study. Methods: Patients with minor bleeding/oozing after elective partial hepatic resection had Fibrocaps applied to the bleeding site either directly from the vial or from a spray device, with manual pressure applied using a cellulose, collagen, or gelatin sponge, if needed. Safety was evaluated at screening and postoperative days 1, 2, and 5, and weeks 4 and 12. The formation of anti-thrombin antibodies was assessed at baseline, and after 4 and 12 weeks. Time to hemostasis (TTH) within 10 min was determined. Results: Twenty-nine patients were treated with Fibrocaps; 6 experienced serious adverse events that were not related to the course of treatment. Adverse events occurring in >10% of patients were nausea, constipation, hypotension, obstipation, hypokalemia, and postoperative pain. Most adverse events were mild or moderate in severity. No patient developed anti-thrombin antibodies. The percentage of patients who achieved hemostasis was 93%; the median TTH was 3.8 min (range 0.3-10.3). Manual pressure was applied with Fibrocaps in 19 patients and considered beneficial in most. Conclusion: Fibrocaps was well tolerated in patients undergoing elective hepatic resection and resulted in rapid hemostasis. These safety and efficacy results support further clinical testing of this ready-to-use fibrin sealant as an adjunct to surgical hemostasis.

Laurent C, Blanc JF, Nobili S, Sa Cunha A, Le Bail B, Bioulac-Sage P, Balabaud C, Capdepont M, Saric J: Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 2005;201:656-662.
Melendez JA, Arslan V, Fischer ME, Wuest D, Jarnagin WR, Fong Y, Blumgart LH: Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 1998;187:620-625.
Paul JE, Ling E, Lalonde C, Thabane L: Deliberate hypotension in orthopedic surgery reduces blood loss and transfusion requirements: a meta-analysis of randomized controlled trials. Can J Anaesth 2007;54:799-810.
Gurusamy KS, Kumar Y, Sharma D, Davidson BR: Methods of vascular occlusion for elective liver resections. Cochrane Database Syst Rev 2007;17:CD006409.
Alkozai EM, Lisman T, Porte RJ: Bleeding in liver surgery: prevention and treatment. Clin Liver Dis 2009;13:145-154.
Erdogan D, Busch OR, Gouma DJ, van Gulik TM: Prevention of biliary leakage after partial liver resection using topical hemostatic agents. Dig Surg 2007;24:294-299.
Berrevoet F, de Hemptinne B: Clinical application of topical sealants in liver surgery: does it work? Acta Chir Belg 2007;107:504-507.
Radosevich M, Goubran HI, Burnouf T: Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997;72:133-143.
Versteeg HH, Heemskerk JW, Levi M, Reitsma PH: New fundamentals in hemostasis. Physiol Rev 2013;93:327-358.
Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, Ravaioli M, Del Gaudio M, Pinna AD: Trends in perioperative outcome after hepatic resection: analysis of 1,500 consecutive unselected cases over 20 years. Ann Surg 2009;249:995-1002.
Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397-406; discussion 406-407.
van den Broek MA, van Dam RM, Malagó M, Dejong CH, van Breukelen GJ, Olde Damink SW: Feasibility of randomized controlled trials in liver surgery using surgery-related mortality or morbidity as endpoint. Br J Surg 2009;96:1005-1014.
De Martino RR, Goodney PP, Spangler EL, Wallaert JB, Corriere MA, Rzucidlo EM, Walsh BD, Stone DH: Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg 2012;55:1035—1040.e4.
Tzeng CW, Katz MH, Fleming JB, Pisters PW, Lee JE, Abdalla EK, Curley SA, Vauthey JN, Aloia TA: Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford) 2012;14:506-513.
Buc E, Dokmak S, Zappa M, Denninger MH, Valla DC, Belghiti J, Farges O: Hepatic veins as a site of clot formation following liver resection. World J Gastroenterol 2011;17:403-406.
Birth M, Figueras J, Bernardini S, Troen T, Günther K, Mirza D, Mortensen FV: Collagen fleece-bound fibrin sealant is not associated with an increased risk of thromboembolic events or major bleeding after its use for hemostasis in surgery: a prospective multicentre surveillance study. Patient Saf Surg 2009;3:13.
Horowitz B, Busch M: Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion 2008;48:1739-1753.
Velthove KJ, Over J, Abbink K, Janssen MP: Viral safety of human plasma-derived medicinal products: impact of regulation requirements. Transfus Med Rev 2013;27:179-183.
Carlson MA, Calcaterra J, Johanning JM, Pipinos II, Cordes CM, Velander WH: A totally recombinant human fibrin sealant. J Surg Res 2014;187:334-342.
Ebner FM, Paul A, Peters J, Hartmann M: Venous air embolism and intracardiac thrombus after pressurized fibrin glue during liver surgery. Br J Anaesth 2011;106:180-182.
Umegaki T, Nishi K, Murao K, Takahira K, Shingu K: Lethal air embolism after spray of tissue adhesive-fibrinogen and factor XIII aerosol during laparoscopic partial nephrectomy. Masui 2007;56:1203-1205.
Olsen PS, Hjelms E: Intravascular air after fibrin sealing by spray gun in cardiovascular surgery. Eur J Cardiothorac Surg 1989;3:376-377.
Sanjay P, Watt DG, Wigmore SJ: Systematic review and meta-analysis of haemostatic and biliostatic efficacy of fibrin sealants in elective liver surgery. J Gastrointest Surg 2013;17:829-836.
Schwartz M, Madariaga J, Hirose R, Shaver TR, Sher L, Chari R, Colonna JO 2nd, Heaton H, Mirza D, Adams R, Rees M, Lloyd D: Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg 2004;139:1148-1154.
Frilling A, Stavrou GA, Mischinger HJ, de Hemptinne B, Rokkjaer M, Klempnauer J, Thörne A, Gloor B, Beckebaum S, Ghaffar MF, Broelsch CE: Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg 2005;390:114-120.
Fischer L, Seiler CM, Broelsch CE, de Hemptinne B, Klempnauer J, Mischinger HJ, Gassel HJ, Rokkjaer M, Schauer R, Larsen PN, Tetens V, Büchler MW: Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery 2011;149:48-55.
Yamashita Y, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Shimada M, Sugimachi K: Bile leakage after hepatic resection. Ann Surg 2001;233:45-50.
Figueras J, Llado L, Miro M, Ramos E, Torras J, Fabregat J, Serrano T: Application of fibrin glue sealant after hepatectomy does not seem justified: results of a randomized study in 300 patients. Ann Surg 2007;245:536-542.
de Boer MT, Klaase JM, Verhoef C, van Dam RM, van Gulik TM, Molenaar IQ, Bosscha K, Dejong CH, Van der Jagt EJ, Porte RJ; FRESCO Trial Group: Fibrin sealant for prevention of resection surface-related complications after liver resection: a randomized controlled trial. Ann Surg 2012;256:229-234.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.